Molecules inhibiting OPG activity result in lower bone mineral density (BMD): as written above for RA; recently autoantibodies against OPG have also been found in SpA, correlating to lower BMD and a history of fractures [27]. This evidence concerns the gene TNFRSF11B and rheumatoid arthritis.